tradingkey.logo


Neuropace Inc

NPCE

8.980USD

-0.010-0.11%
āđ€āļ§āļĨāļēāļ—āļģāļāļēāļĢāļ•āļĨāļēāļ” ETāļĢāļēāļ„āļēāļĨāđˆāļēāļŠāđ‰āļē 15 āļ™āļēāļ—āļĩ
294.11MāļĄāļđāļĨāļ„āđˆāļēāļ•āļĨāļēāļ”
āļ‚āļēāļ”āļ—āļļāļ™P/E TTM

āļĢāļēāļĒāļĨāļ°āđ€āļ­āļĩāļĒāļ”āđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄāļ‚āļ­āļ‡ Neuropace Inc āļšāļĢāļīāļĐāļąāļ—
NeuroPace, Inc. is a medical device company. The Company is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The Company has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorder.
āļ‚āđ‰āļ­āļĄāļđāļĨāļšāļĢāļīāļĐāļąāļ—
āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™NPCE
āļŠāļ·āđˆāļ­āļšāļĢāļīāļĐāļąāļ—Neuropace Inc
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļApr 22, 2021
āļ‹āļĩāļ­āļĩāđ‚āļ­Mr. Joel D. Becker
āļˆāļģāļ™āļ§āļ™āļžāļ™āļąāļāļ‡āļēāļ™184
āļ›āļĢāļ°āđ€āļ āļ—āļāļēāļĢāļĢāļąāļāļĐāļēāļ„āļ§āļēāļĄāļ›āļĨāļ­āļ”āļ āļąāļĒOrdinary Share
āļŠāļīāđ‰āļ™āļ›āļĩāļ‡āļšāļ›āļĢāļ°āļĄāļēāļ“Apr 22
āļ—āļĩāđˆāļ­āļĒāļđāđˆ455 N. Bernardo Avenue
āđ€āļĄāļ·āļ­āļ‡MOUNTAIN VIEW
āļ•āļĨāļēāļ”āļŦāļĨāļąāļāļ—āļĢāļąāļžāļĒāđŒNASDAQ Global Market Consolidated
āļ›āļĢāļ°āđ€āļ—āļĻUnited States of America
āļĢāļŦāļąāļŠāđ„āļ›āļĢāļĐāļ“āļĩāļĒāđŒ94043
āđ‚āļ—āļĢāļĻāļąāļžāļ—āđŒ16502372700
āđ€āļ§āđ‡āļšāđ„āļ‹āļ•āđŒhttps://www.neuropace.com/
āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™NPCE
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļApr 22, 2021
āļ‹āļĩāļ­āļĩāđ‚āļ­Mr. Joel D. Becker
āļœāļđāđ‰āļšāļĢāļīāļŦāļēāļĢāļšāļĢāļīāļĐāļąāļ—
āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Mr. Frank M. Fischer
Mr. Frank M. Fischer
Independent Chairman of the Board
Independent Chairman of the Board
589.53K
+0.39%
Dr. Martha J. Morrell, M.D.
Dr. Martha J. Morrell, M.D.
Chief Medical Officer
Chief Medical Officer
74.39K
-1.77%
Mr. Patrick F. Williams
Mr. Patrick F. Williams
Chief Financial Officer
Chief Financial Officer
51.85K
--
Mr. Joseph S. (Joe) Lacob
Mr. Joseph S. (Joe) Lacob
Independent Director
Independent Director
37.35K
+2.98%
Ms. Rakhi Kumar, CPA
Ms. Rakhi Kumar, CPA
Independent Director
Independent Director
15.59K
+10.17%
Dr. Uri Geiger
Dr. Uri Geiger
Independent Director
Independent Director
12.04K
+10.46%
Mr. R. Scott (Scott) Huennekens
Mr. R. Scott (Scott) Huennekens
Independent Director
Independent Director
--
--
Ms. Renee Ryan
Ms. Renee Ryan
Independent Director
Independent Director
--
--
Mr. Joel D. Becker
Mr. Joel D. Becker
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Lisa Andrade
Ms. Lisa Andrade
Independent Director
Independent Director
--
--
āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Mr. Frank M. Fischer
Mr. Frank M. Fischer
Independent Chairman of the Board
Independent Chairman of the Board
589.53K
+0.39%
Dr. Martha J. Morrell, M.D.
Dr. Martha J. Morrell, M.D.
Chief Medical Officer
Chief Medical Officer
74.39K
-1.77%
Mr. Patrick F. Williams
Mr. Patrick F. Williams
Chief Financial Officer
Chief Financial Officer
51.85K
--
Mr. Joseph S. (Joe) Lacob
Mr. Joseph S. (Joe) Lacob
Independent Director
Independent Director
37.35K
+2.98%
Ms. Rakhi Kumar, CPA
Ms. Rakhi Kumar, CPA
Independent Director
Independent Director
15.59K
+10.17%
Dr. Uri Geiger
Dr. Uri Geiger
Independent Director
Independent Director
12.04K
+10.46%
āļŠāļąāļ”āļŠāđˆāļ§āļ™āļ‚āļ­āļ‡āļĢāļēāļĒāđ„āļ”āđ‰
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q1
FY2023
FY2022
FY2021
FY2020
FY2019
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
āļ•āļēāļĄāļ āļđāļĄāļīāļ āļēāļ„USD
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
United States
22.52M
0.00%
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆ
āļ•āļēāļĄāļ āļđāļĄāļīāļ āļēāļ„
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
āļŠāļ–āļīāļ•āļīāļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļžāļļāļ˜āļ—āļĩāđˆ 4 āļĄāļī.āļĒ.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļžāļļāļ˜āļ—āļĩāđˆ 4 āļĄāļī.āļĒ.
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Accelmed Growth Partners Management Ltd
13.52%
OrbiMed Advisors, LLC
10.39%
Soleus Capital Management, L.P.
7.95%
Morgan Stanley & Co. LLC
7.70%
Polar Capital LLP
7.62%
Other
52.83%
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Accelmed Growth Partners Management Ltd
13.52%
OrbiMed Advisors, LLC
10.39%
Soleus Capital Management, L.P.
7.95%
Morgan Stanley & Co. LLC
7.70%
Polar Capital LLP
7.62%
Other
52.83%
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Private Equity
23.90%
Hedge Fund
20.38%
Investment Advisor/Hedge Fund
19.42%
Investment Advisor
13.63%
Research Firm
8.48%
Individual Investor
2.75%
Pension Fund
0.40%
Bank and Trust
0.04%
Insurance Company
0.02%
Other
10.96%
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡āļŠāļ–āļēāļšāļąāļ™î™Œ
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļąāļ‡āļ„āļēāļĢāļ—āļĩāđˆ 1 āļ.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļąāļ‡āļ„āļēāļĢāļ—āļĩāđˆ 1 āļ.āļ„.
āļŠāđˆāļ§āļ‡āđ€āļ§āļĨāļēāļāļēāļĢāļĢāļēāļĒāļ‡āļēāļ™
āļˆāļģāļ™āļ§āļ™āļŠāļ–āļēāļšāļąāļ™
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
2025Q2
183
29.20M
89.03%
-971.50K
2025Q1
183
29.76M
92.98%
+2.27M
2024Q4
144
26.53M
86.07%
-49.99K
2024Q3
134
26.01M
86.62%
-1.02M
2024Q2
129
25.88M
90.53%
+502.69K
2024Q1
131
24.82M
87.55%
-513.24K
2023Q4
113
24.06M
92.70%
-1.70M
2023Q3
103
24.86M
97.20%
-1.10M
2023Q2
106
24.30M
96.22%
-2.15M
2023Q1
107
24.47M
97.75%
-1.64M
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
āļāļīāļˆāļāļĢāļĢāļĄāļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™î™Œ
āļŠāļ·āđˆāļ­
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™%
āļ§āļąāļ™āļ—āļĩāđˆ
Accelmed Growth Partners Management Ltd
4.43M
13.52%
--
--
Apr 09, 2025
OrbiMed Advisors, LLC
3.41M
10.39%
--
--
Mar 31, 2025
Soleus Capital Management, L.P.
2.61M
7.95%
+175.00K
+7.19%
Mar 31, 2025
Morgan Stanley & Co. LLC
2.52M
7.7%
+38.83K
+1.56%
Mar 31, 2025
Polar Capital LLP
2.50M
7.62%
-472.00K
-15.88%
Apr 09, 2025
First Light Asset Management, LLC
1.58M
4.83%
+1.58M
--
Mar 31, 2025
The Vanguard Group, Inc.
1.20M
3.65%
+140.78K
+13.32%
Mar 31, 2025
Armistice Capital LLC
1.15M
3.52%
+561.00K
+94.67%
Mar 31, 2025
Kent Lake PR LLC
950.00K
2.9%
-532.55K
-35.92%
Mar 31, 2025
DWS Investments UK Limited
923.92K
2.82%
+511.66K
+124.11%
Mar 31, 2025
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
ETF āļ—āļĩāđˆāđ€āļāļĩāđˆāļĒāļ§āļ‚āđ‰āļ­āļ‡î™Œ
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 2 āļŠ.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 2 āļŠ.āļ„.
āļŠāļ·āđˆāļ­
āļŠāļąāļ”āļŠāđˆāļ§āļ™
iShares Neuroscience and Healthcare ETF
0.63%
iShares Micro-Cap ETF
0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.03%
iShares Russell 2000 Growth ETF
0.02%
Principal U.S. Small-Cap ETF
0.02%
Invesco Russell 2000 Dynamic Multifactor ETF
0.01%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 ETF
0.01%
ProShares UltraPro Russell2000
0.01%
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
iShares Neuroscience and Healthcare ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.63%
iShares Micro-Cap ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.03%
iShares Russell 2000 Growth ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.02%
Principal U.S. Small-Cap ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.02%
Invesco Russell 2000 Dynamic Multifactor ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.01%
Global X Russell 2000 ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.01%
ProShares Hedge Replication ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.01%
iShares Russell 2000 ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.01%
ProShares UltraPro Russell2000
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.01%
āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ
āļĄāļĩāļāļēāļĢāļˆāđˆāļēāļĒāđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨāđ€āļ›āđ‡āļ™āļˆāļģāļ™āļ§āļ™āļĢāļ§āļĄ 0.00 USD āđƒāļ™āļŠāđˆāļ§āļ‡ 5 āļ›āļĩāļ—āļĩāđˆāļœāđˆāļēāļ™āļĄāļē
āļ§āļąāļ™āļ—āļĩāđˆ
āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ
āļ§āļąāļ™āļ—āļĩāđˆāļšāļąāļ™āļ—āļķāļ
āļ§āļąāļ™āļ—āļĩāđˆāļŠāļģāļĢāļ°āđ€āļ‡āļīāļ™
āļ§āļąāļ™āļ—āļĩāđˆāđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļŠāļīāļ—āļ˜āļīāļ›āļąāļ™āļœāļĨ
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
āļāļēāļĢāđāļšāđˆāļ‡āļŦāļļāđ‰āļ™î™Œ
āļ§āļąāļ™āļ—āļĩāđˆ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
āļ§āļąāļ™āļ—āļĩāđˆ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
KeyAI
î™